Experience

Davis Polk advised the sole initial purchaser in connection with a Rule 144A offering by The Medicines Company of $150 million aggregate principal amount of 3.50% convertible senior…

Davis Polk advised the initial purchasers in connection with a Rule 144A and Regulation S offering by iQIYI, Inc. of $750 million aggregate principal amount of its 3.75% convertible…

Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $850 million aggregate principal amount of its 0.75% senior…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Electronics For Imaging, Inc. of $150 million aggregate principal amount of its 2.25% convertible senior…

Davis Polk advised Orogen on its $150 million investment in ExlService Holdings, Inc. Under the terms of the investment, Orogen is purchasing $150 million in aggregate principal amount of 3…

Davis Polk acted as special product counsel to the representatives of the several underwriters in connection with the $977.5 million SEC-registered offering of 19,550,000 depositary…

Davis Polk advised Shire plc on concurrent tender offers by Baxalta Incorporated and Shire Acquisitions Investments Ireland DAC (“SAIIDAC”), both wholly owned subsidiaries of Shire,…

Davis Polk advised the joint bookrunners and joint lead managers in connection with a Regulation S offering of $215 million currency linked zero coupon convertible bonds due 2023 by…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 8,060,550 shares of common stock of DocuSign, Inc. by certain existing…

Davis Polk advised the sole book-running manager in connection with a registered offering by Infinera Corporation of $402.5 million aggregate principal amount of 2.125% convertible…